For example, PD-L1 expression in tumor cells is associated with improved response and survival in patients with advanced NSCLC treated with pembrolizumab, but this correlation does not hold true for patients with melanoma or RCC [10]. This evidence concerns the gene CD274 and renal cell carcinoma.